Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Aeon Biopharma Inc

AEON ✓ COMPLIANT ☆ Track — members

NYSE American · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.28

▲ +1.66%

Market Cap $13.72M · Vol 15.78K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$13.72M

Micro Cap

Div Yield

N/A

EPS Growth

+71.43%

YoY

RSI (14)

57.22

Momentum

Beta

0.64

vs Market

52W High

$1.44

80.90% below

52W Low

$0.23

21.89% above

Volume

15.78K

Avg 33.00K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

61.68%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Aeon Biopharma Inc (AEON) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AEON pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.72%

-22.94%

-65.66%

-72.49%

YTD

-74.99%

-64.73%

-99.91%

-99.96%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-39,222,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-901.45% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+71.43%
Outstanding Shares	49.88M

Technical Indicators

50-Day SMA	$0.48
200-Day SMA	$0.86
RSI (14)	57.22
Beta	0.64
52-Week High	$1.44
52-Week Low	$0.23

Volume Today	15.78K
Avg Daily Volume (30D)	33.00K
Relative Volume	0.48x
Volatility (10D)	22.25
Volatility (30D)	164.25
Free Float	61.68%

Analyst Consensus

BUY

Current Price $0.28

Mean Target $3.80

52W Low$0.23 52W High$1.44

Current

Target

$0.23 $1.44

Current Analyst target

+1,281.32% upside potential · 1 analysts

Identifiers

ExchangeNYSE American

FIGIBBG00Z17HFQ5

ISINUS00791X2099

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.